Odyssey Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed Jun 17, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Jun 17, 2026
ODTX$20.00+4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $35,719 | $41,687 |
| Short-term marketable securities | 140,030 | 139,671 |
| Prepaid expenses and other current assets | 9,352 | 9,298 |
| Total current assets | 185,101 | 190,656 |
| Property and equipment, net | 6,556 | 7,209 |
| Right-of-use assets | 17,920 | 18,804 |
| Goodwill | 14,072 | 14,327 |
| Intangible asset | 160 | 262 |
| Long-term marketable securities | - | 35,198 |
| Other non-current assets | 5,261 | 3,332 |
| Total assets | $229,070 | $269,788 |
| Liabilities, Convertible Preferred Stock and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $8,219 | $7,872 |
| Accrued expenses and other current liabilities | 8,618 | 13,392 |
| Lease liabilities, current | 5,374 | 5,211 |
| Total current liabilities | 22,211 | 26,475 |
| Contingent consideration and warrant liability | 6,242 | 6,133 |
| Lease liabilities, non-current | 20,753 | 21,900 |
| Total liabilities | 49,206 | 54,508 |
| Commitments and contingencies (see Note 14) | ||
| Series A convertible preferred stock, net of issuance costs, $0.0001 par value: 43,749,045 shares authorized as of March 31, 2026 and December 31, 2025; and 43,732,797 shares issued and outstanding as of March 31, 2026 and December 31, 2025 (liquidation preference $84,796 as of March 31, 2026 and December 31, 2025) | 216,503 | 216,503 |
| Series B convertible preferred stock, net of issuance costs, $0.0001 par value: 26,601,360 shares authorized as of March 31, 2026 and December 31, 2025; and 26,601,360 shares issued and outstanding as of March 31, 2026 and December 31, 2025 (liquidation preference $66,100 as of March 31, 2026 and December 31, 2025) | 167,765 | 167,765 |
| Series C convertible preferred stock, net of issuance costs, $0.0001 par value: 24,901,598 shares authorized as of March 31, 2026 and December 31, 2025; and 24,901,598 shares issued and outstanding as of March 31, 2026 and December 31, 2025 (liquidation preference $49,065 as of March 31, 2026 and December 31, 2025) | 123,259 | 123,259 |
| Series D convertible preferred stock, net of issuance costs, $0.0001 par value: 142,016,823 shares authorized as of March 31, 2026 and December 31, 2025; and 141,950,377 shares issued and outstanding as of March 31, 2026 and December 31, 2025 (liquidation preference $213,631 as of March 31, 2026 and December 31, 2025) | 196,031 | 196,031 |
| Stockholders’ deficit: | ||
| Common stock, $0.0001 par value: 365,081,240 shares authorized as of March 31, 2026 and December 31, 2025; 2,634,650 shares and 2,472,757 shares issued as of March 31, 2026 and December 31, 2025, respectively; 2,481,339 shares and 2,306,207 shares outstanding as of March 31, 2026 and December 31, 2025, respectively | - | - |
| Additional paid-in capital | 82,854 | 79,616 |
| Accumulated deficit | (606,401) | (568,139) |
| Accumulated other comprehensive income (loss) | (147) | 245 |
| Total stockholders’ deficit | (523,694) | (488,278) |
| Total liabilities, convertible preferred stock, and stockholders’ deficit | $229,070 | $269,788 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.